ABSTRACT

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19. Until now, diverse drugs have been used for the treatment of COVID-19. These drugs are associated with severe side effects, e.g. induction of erythrocyte death, named eryptosis. This massively affects the oxygen (O₂) supply of the organism. Therefore, three elementary aspects should be considered simultaneously: (1) a potential drug should directly attack the virus, (2) eliminate virus-infected host cells and (3) preserve erythrocyte survival and functionality. It is known that PKC-α inhibition enhances the vitality of human erythrocytes, while it dose-dependently activates the apoptosis machinery in nucleated cells. Thus, the use of chelerythrine as a specific PKC-alpha and -beta (PKC-α/-β) inhibitor should be a promising approach to treat people infected with SARS-CoV-2.

摘要

严重的急性呼吸综合症冠状病毒2（SARS-CoV-2）导致COVID-19。迄今为止，已经使用了多种药物来治疗COVID-19。这些药物与严重的副作用有关，例如诱导红细胞死亡，称为隐匿性。这会严重影响氧气（O ₂）生物体的供应。因此，应同时考虑三个基本方面：（1）潜在的药物应直接攻击病毒；（2）消除感染了病毒的宿主细胞；（3）保留红细胞的存活和功能。已知PKC-α抑制可增强人红细胞的活力，而剂量依赖性地激活有核细胞中的凋亡机制。因此，白屈菜红碱作为一种特定的PKC-α和-β（PKC-α/-β）抑制剂的使用应该是治疗感染SARS-CoV-2的人的有前途的方法。